Yes I think this post explains the opportunities.
Again excellent post from Wombat and Oldtimer72!
As posted in the response by @Oldtimer72, there are two opportunities:
I envisage that as they ramp down treatment of COVID-19 ARDS they will be able to ramp up treatment of Non-COVID ARDS.
- Treatment of ARDS associated with COVID-19 infection
- Treatment of ARDS associated with a wide range of other causes (see below). This is a much larger opportunity that will exist beyond COVID-19.
From https://ardsglobal.org/acute-respiratory-distress-syndrome/ ...
Possible Precipitating Causes
I tallied the data. There are around 2.3M cases of ARDS per annum in the world. Around 70% of these are moderate and severe to the point that they require invasive mechanical ventilation.
- Shock
- Severe blood loss
- Bone fractures – if they cause shock.
- Severe infections
- Bacterial lung infection
- Viral lung infection
- Fungal lung infection
- Lung trauma
- Drowning
- Water inhalation
- Vomit inhalation
- Pneumonia
- Sepsis
- Poliomyelitis
- Blood transfusion adverse reaction (type of Adverse reaction)
- Heart bypass surgery adverse reaction (type of Adverse reaction)
- Smoke inhalation
- Toxic fume inhalation
- Circulatory collapse
- Sepsis
- Asthma
- Emphysema
- Muscular dystrophy
- Pancreatitis
- Guillaine-Barre syndrome
- Uremia
- Myasthenia gravis
Just in the US and European Top 5 countries, around 230,000 cases of moderate and severe ARDS each year. I only included these regions since this is probably where approvals and partnership deals might occur first.
No lightbulbs please. Maybe refer Wombats original and give it it's just reward!
- Forums
- ASX - By Stock
- MSB
- Will Moderna Vaccine progress effect MSB SP?
Will Moderna Vaccine progress effect MSB SP?, page-24
-
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
|
|||||
Last
97.0¢ |
Change
-0.005(0.51%) |
Mkt cap ! $1.107B |
Open | High | Low | Value | Volume |
98.5¢ | 98.5¢ | 96.0¢ | $2.168M | 2.226M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 16000 | 96.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
97.0¢ | 86854 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 16000 | 0.965 |
1 | 23000 | 0.960 |
4 | 56273 | 0.955 |
5 | 46225 | 0.950 |
2 | 65500 | 0.945 |
Price($) | Vol. | No. |
---|---|---|
0.970 | 50000 | 2 |
0.975 | 20000 | 1 |
0.980 | 894 | 1 |
0.985 | 48122 | 2 |
0.990 | 54328 | 5 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
MSB (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online